Clinical Trial Imaging Market Size, Share, and Growth Forecast for 2025 - 2032

The global clinical trial imaging market size is anticipated to rise from US$ 1.5 Bn in 2025 to US$ 2.5 Bn by 2032. It is projected to witness a CAGR of 7.5% from 2025 to 2032.

The market for clinical trial imaging benefits drug development immensely by providing precise imaging data for assessing treatment efficacy and safety.

• According to World Health Organization 39,952, clinical trials were conducted in 2024, which is considered to be a huge number.

The increasing number of trials taking place is boosting the market prospects to witness substantial growth over the forecast period.

The market includes a variety of imaging modalities such as CT, MRI, X-ray, ultrasound, and PET/SPECT, which are commonly utilized in oncology, neurology, cardiology, and other therapeutic fields. The increasing number of clinical trials, advancements in imaging technologies, and expanding adoption of this technology are pushing the market forward.

Pharmaceutical and biotechnology companies, along with contract research organizations (CROs), are the primary users of imaging solutions, leveraging them for biomarker identification, disease monitoring, and regulatory approvals. The rise of decentralized clinical trials, cloud-based imaging systems, and regulatory standards defines the industry's future, creating considerable prospects for innovation and market growth.

Key Highlights of the Market

• X-Rays dominates the modality segment with 21% market share owing to its efficacy and timely results.
• Oncology Leads the therapeutic area segmentation as most of the clinical trials worldwide focus on cancer treatment.
• North America holds the largest market share at 28%, as it is home to major pharmaceutical corporations, CROs, and regulatory organizations (FDA).
• Asia Pacific is the fastest-growing market as China, India, and Japan are emerging as important hubs for outsourced clinical trials.
• With strong regulatory frameworks for clinical trial imaging in the region, Europe owns a substantial market share.

Advancements in Imaging Technology Spurred Market Growth Pre-2024

During the historical period from 2019 to 2024, the market for clinical trial imaging has grown significantly over the last decade. The growth of the market was primarily attributed to the advances in imaging technology, increased clinical trial activity, and regulatory emphasis on imaging biomarkers.

AI-driven automation, cloud-based imaging, and decentralized trial solutions will shape the market's future. AI-powered imaging biomarkers will be critical for early illness detection and therapy response evaluation, especially in oncology and neurology studies.

Cloud-based imaging tools will drive decentralized and virtual trials, increasing accessibility while lowering costs. The coming decade will see a data-driven, AI-powered revamp of clinical trial imaging.  

Adoption of Sophisticated Imaging Technologies Bolsters Market Growth

Over the forecast period, the market is poised for continued growth with the adoption of sophisticated imaging technologies. Technologies like AI-enabled body scans are expected to rise, facilitating early detection of health conditions and improving patient outcomes. ?

Regions like Asia Pacific are anticipated to witness accelerated growth due to increasing clinical trial activities, expanding healthcare infrastructure, and a growing patient population. Governments and regulatory bodies are likely to implement favorable policies to encourage innovation and efficiency in clinical trials, further propelling market expansion.

Growth Driver

Rise of Virtual and Hybrid Clinical Trials Fuels Demand for Remote Imaging Solutions

The growing adoption of virtual and hybrid clinical trials is significantly increasing the demand for remote imaging solutions in the healthcare and pharmaceutical industries. The shift is driven by the need for greater efficiency, accessibility, and patient convenience in clinical research.

Remote imaging technology enables the seamless collection, review, and analysis of medical images without requiring patients to be physically present at trial sites. Through secure cloud-based platforms, clinical researchers can access, monitor, and analyse imaging data in real time, ensuring faster decision-making, improved data accuracy, and enhanced patient compliance.

The innovation not only reduces logistical challenges but also broadens patient recruitment opportunities by allowing participation from diverse geographic locations. As the clinical trial industry continues to embrace digital transformation, the demand for AI-driven imaging solutions will continue to grow, reshaping the future of clinical research and drug development worldwide.

• As per studies by Persistence Market Research, 70% of pharmaceutical sponsors plan to implement hybrid or fully decentralized clinical trials within the next 12 months, particularly in therapeutic areas such as oncology, rare diseases, and infectious diseases.

Market Restraining Factor

High Costs of Imaging Technology and Services Impedes Market Expansion

Advanced imaging techniques require expensive equipment, skilled personnel, and significant operational costs. The adoption of modern imaging techniques in clinical trials is restricted by high equipment costs, the requirement for trained professionals, and large operational expenses.

MRI, PET, and 4D imaging require cutting-edge scanners, dedicated imaging centres, and highly trained radiologists, which raises overall trial expenses. Maintenance, software upgrades, and compliance with regulatory standards all contribute to cost constraints.

The high-cost issues are especially acute in underdeveloped or emerging countries, where access to cutting-edge imaging infrastructure is scarce. High costs and resource constraints may cause trial delays and lower acceptance of AI-driven imaging solutions, limiting overall market growth.

Key Market Opportunity

Remote and Decentralized Imaging in Hybrid Trials Propels Market Demand

The shift towards hybrid and decentralized clinical trials presents a significant opportunity for remote imaging solutions. Traditional clinical trials require patients to visit trial sites for imaging procedures, which can be a barrier, especially for those in rural or underserved areas.

Cloud-based imaging platforms, mobile imaging units, and telemedicine integration are now enabling patients to participate in trials from remote locations. The patient-centric approach improves recruitment, retention, and data diversity, making trials more inclusive and representative.

• In March 2023, Clario introduced a cloud-based Image Viewer tool, enabling sponsors and CROs to access and manipulate clinical trial images in real time. This innovation streamlines image accessibility within a secure, integrated system.

Secure cloud storage and AI-driven image processing ensure that imaging data can be accessed and analysed in real-time, reducing delays and enhancing trial efficiency. Further, the growing adoption of remote imaging is set to revolutionize the way clinical trials are conducted, making research more scalable, efficient, and globally connected.

Modality Insights

X-Ray Leads with 21% Share Owing to its Efficacy and Timely Results

X-ray imaging remains one of the most widely utilized diagnostic tools in modern healthcare, playing a crucial role in disease detection, treatment monitoring, and clinical trial imaging.

As a standard imaging procedure, X-rays are extensively used to capture internal body structures, particularly bones, allowing healthcare professionals to track disease progression, assess treatment efficacy, and measure critical parameters such as tumour size over time.

In clinical trials, X-ray imaging provides researchers with valuable insights into how a study drug or intervention impacts patients, ensuring data accuracy and improved medical outcomes. The growing reliance on X-rays reflects the increasing demand for advanced imaging technologies as global healthcare access continues to expand.

The rising adoption of cutting-edge X-ray systems is further boosting the clinical trial imaging market. As imaging technology advances, the role of X-rays in clinical trials and precision medicine will continue to evolve, driving innovation in medical imaging solutions worldwide.

• For instance, in March 2024, Shimadzu introduced the RADspeed Pro SR5 Version, a next-generation radiography system designed for enhanced patient monitoring, seamless digital radiography (DR) integration, and automated functionalities.

Therapeutic Area Insights

Oncology Leads the Therapeutic Area Segmentation with 23% Share Due to growing Number of Cancer Patients Globally

Imaging is a crucial component of cancer research, playing a key role in early detection, disease staging, treatment monitoring, and biomarker evaluation. As cancer rates continue to rise globally, the demand for advanced imaging solutions in oncology clinical trials is growing rapidly.

• According to the World Cancer Research Fund, 19.9 million people were diagnosed with cancer in 2022, and this number is steadily increasing.

The rising incidence of cancer has led to a surge in oncology-focused clinical trials, driving the need for high-quality clinical trial imaging to assess the effectiveness of new therapies. As a result, pharmaceutical and biotechnology companies are making significant investments in oncology clinical trials, making this segment the largest revenue contributor in the clinical trial imaging market.

• For instance, in January 2025, Quibim, a Spanish medical imaging firm, secured US$ 50 million in Series A funding to develop AI-driven imaging models for oncology, immunology, neurology, and metabolic disorders.

North America Clinical Trial Imaging Market to Dominate with 28% Share Due to Strong R&D and Innovation

North America holds the largest share of the global market for clinical trial imaging, which is primarily driven by robust R&D investments, advanced healthcare infrastructure, and supportive regulatory policies.

The region continues to lead in AI-powered imaging, machine learning analytics, and cloud-based imaging solutions, transforming the landscape of clinical research and drug development.

North America remains at the forefront of medical imaging advancements, particularly in addressing cardiovascular, neurological, and oncology-related conditions.

• In December 2024, Philips introduced the CT 5300 in North America, an advanced AI-powered imaging system designed to provide high-quality screening, diagnostics, and interventional imaging to a broader patient population.

US Clinical Trial Imaging Market

The US is a global leader in clinical trials, with major pharmaceutical companies such as Pfizer, Merck, and Johnson & Johnson investing heavily in innovative drug research and precision medicine.

• According to the World Health Organization (WHO), the U.S. accounted for 20.5% of global clinical trial activity in 2024, highlighting its dominance in the sector.

The US has witnessed significant growth in healthcare expenditures, reflecting increased investment in medical research and advanced imaging technologies.

• According to a CMS report published in Health Affairs, US healthcare spending grew by 7.5% in 2023, reaching US$ 4.9 trillion, compared to 4.2% in 2021 and 4.6% in 2022.

Europe Clinical Trial Imaging Market to Own Substantial Market Share with Strong Regulatory Frameworks & High-end Healthcare Infrastructure

Europe holds a significant market share in the global clinical trial imaging industry, supported by a well-established healthcare infrastructure, stringent regulatory frameworks, and substantial investments in pharmaceutical research.

The region continues to advance in medical imaging technologies, ensuring high-quality standards in clinical trial imaging. Europe remains a hub for clinical research, with a growing number of trials incorporating advanced imaging technologies for precise analysis.

• According to available data, in 2024, approximately 44,258 clinical trials were registered in the EU Clinical Trials Register, many of which relied on imaging solutions to assess treatment efficacy and disease progression.

The European Medicines Agency (EMA) has set comprehensive guidelines for imaging use in clinical studies, ensuring high-quality standards and consistency. The EU Clinical Trials Regulation (CTR) has simplified regulatory processes, enabling more efficient cross-border clinical trials and further driving market growth.

As pharmaceutical companies continue to invest in imaging technologies and regulatory bodies streamline trial processes, Europe’s clinical trial imaging sector is set for sustained growth and innovation.

Asia Pacific Clinical Trial Imaging Market to Witness Fastest-Growth with the Rapid Increase in Clinical Trial Activity

Asia Pacific is emerging as the fastest-growing market for clinical trial imaging, driven by advancements in healthcare infrastructure and a significant increase in clinical trial activity.

Countries such as China and India are making substantial investments in biopharmaceutical research and development, fueling the demand for advanced imaging solutions in clinical trials.

• According to the World Health Organization (WHO), in 2024, China conducted 23,768 clinical trials, representing 21.6% of the global share, while India accounted for 19,923 trials, making up 17.8% of the global total.

The region has become a global leader in clinical trial volume, benefiting from lower operational costs, faster patient recruitment, and access to diverse patient populations.

As Asia Pacific strengthens its position in global clinical research, the demand for clinical trial imaging solutions will continue to rise, making the region a key driver of innovation and market expansion.

The market for clinical trial imaging is highly competitive, with key players focusing on technological advancements, strategic partnerships, and geographic expansion to strengthen their market presence.

Leading companies in the industry are investing in AI-powered imaging solutions, cloud-based platforms, and advanced analytics to enhance clinical trial efficiency. The market is witnessing a rise in mergers and acquisitions as companies aim to expand service portfolios and improve imaging capabilities.

The growing adoption of remote imaging and real-time data analysis is reshaping the competitive landscape. With the increasing demand for precision medicine and AI-driven diagnostics, companies that prioritize innovation and regulatory compliance are set to gain a competitive edge.

Recent Industry Developments

• In January 2025, Isotropic announced a timeline for its upcoming clinical study for FDA approval of its first medical imaging device, the IzoView Breast CT Imaging System ("IzoView"), with contrast enhancement for breast cancer screening in addition to digital breast tomosynthesis ("DBT"), also known as 3D mammography for patients with dense breast tissue.
• In June 2024, Pie Medical Imaging, a leader in cardiac imaging worldwide, reported enrollment in the multi-center randomized clinical trial FASTIII, which examines the application of angiography-based vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary revascularization procedures, is now complete.
• In May 2024, Siemens Healthineers and Blue Earth Diagnostics have agreed to share clinical data for the PET imaging agent POSLUMA® (Flotufolastat F 18) to facilitate the development of AI-based algorithms. 
• In March 2024, ARPA-H and the FDA announced a partnership on medical imaging data by lowering obstacles to acquiring data that satisfies regulatory quality criteria, the agencies hope to create a medical imaging data marketplace (MIDM) that will spur AI and ML innovation.